Related Experiment Videos
Surgical Outcomes for Hidradenitis Suppurativa: Does Biologic Therapy Make a Difference?
Nicole Schiraldi1,2, Richard Rookwood1, Yael Weitzner1
1Division of Dermatology, Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York.
Summary
Biologic therapy for hidradenitis suppurativa (HS) did not negatively impact surgical healing or increase complications. This finding supports the safe combination of biologics with excisional surgery for HS patients.
Area of Science:
- Dermatology
- Surgical Oncology
- Immunology
Background:
- Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition requiring medical and surgical management.
- Biologic therapies are increasingly used for moderate-to-severe HS, but their impact on surgical outcomes is not well-defined.
Purpose of the Study:
- To evaluate the effect of biologic therapy on postoperative outcomes in patients undergoing excisional surgery for HS.
- Assessing the safety and efficacy of combining biologic treatments with surgical interventions for HS.
Main Methods:
- Retrospective chart review of adult HS patients undergoing excisional surgery.
- Collected data on demographics, comorbidities, disease severity, biologic use (adalimumab, infliximab), and surgical outcomes.
- Compared outcomes between biologic and nonbiologic groups using statistical analyses with false discovery rate correction.
Main Results:
- 27.4% of 109 excisions were performed in patients on biologic therapy.
- Biologic group patients had more severe (Hurley Stage III) disease and greater surgical burden.
- No significant differences were observed in healing time, complication rates, recurrence, or need for revision surgery between groups.
Conclusions:
- Biologic therapy does not appear to impair postoperative healing in HS patients undergoing surgery.
- Combining biologic treatments with excisional surgery for HS is supported as a safe approach.
- Further research may elucidate long-term effects and optimize treatment strategies.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Inflammatory Bowel Disease V: Surgical Management
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD: